Entera Announces Third Quarter 2026 Financial Results and Business Updates

Miranda Toledano, Chief Executive Officer of Entera

“The third quarter of 2026 transitioned our expanding team into late-stage clinical execution mode. The opportunity to evaluate the safety and efficacy of EB613 as the first oral anabolic treatment for osteoporosis has generated excitement among clinical investigators and patients. Our team is fully focused on ensuring a seamless trial launch, with expected first site activation in late 2026. Additionally, the post-hoc analysis that we presented at ASBMR 2026 demonstrated that our Phase 2 6-month clinical data with EB613 show rapid stimulation of bone formation and robust early bone mineral density (BMD) accrual, especially in patients who start with lower BMD and who need the largest gains. These are the women we plan to enroll in our Phase 3 study. Finally, we continue to invest in expanding our human capital at Entera with early and late-stage clinical leadership and board appointments.”